All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

An expert panel hosted by

The Lymphoma Hub logo and the Multiple Myeloma Hub logo

Sequencing immune-based therapies in B-cell malignancies

with Ulric Jäger, Sagar Lonial, and Krina Patel

Saturday, June 15 | 18:00-19:30 CEST

Register now

This independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.


The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Prof. Marek Trneny | EBMT 2018 | What were the most interesting results from EBMT?

Mar 23, 2018

Prof. Marek Trneny discusses key results from the 44th Annual Meeting of the European Society for Blood and Marrow Transplantation from the following abstracts:

- Abstract OS1-3: Monica Baile on behalf of GELTAMO: Lenalidomide together with R-ESHAP shows significant activity in relapsed/refractory DLBCL (ORR 65% and CR 37%), to note: on third of pts were not R/R but PRs only after the induction
- Abstract OS1-7: Enrico Derenzini on behalf of Italian centers: Pretransplant  immune checkpoint activation (PD1/PDL1 and LAG3) is connected with worse outcome after alloSCT
- Abstract OS1-6: Leopold Sellner on behalf of LWP EBMT: Idelalisib treatment for follicular lymphoma as bridging before alloSCT is feasible, with 70% PFS and 71% OS at 12 months
- Abstract WP7-6: Anne-Claire Mamez on behalf of French-speaking Europe: Promising results of AlloSCT in T-cell lymphomas, n 284, 2years OS and PFS were 68% and 64% resp

What were the most interesting results from EBMT?

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you


Subscribe to get the best content related to lymphoma & CLL delivered to your inbox